Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Tirani, Marcello ^a   Meregaglia, Michela ^b   Melegaro, Alessia ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; 4CMENB VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH ECONOMICS; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; INFECTION CONTROL; ITALY; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MENINGOCOCCOSIS; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; COST BENEFIT ANALYSIS; ECONOMICS; MENINGITIS, BACTERIAL; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; QUALITY OF LIFE; SEROTYPE; YOUNG ADULT;

BACTERIA (MICROORGANISMS);

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; INFANT, NEWBORN; ITALY; MALE; MENINGITIS, BACTERIAL; MENINGOCOCCAL VACCINES; MIDDLE AGED; QUALITY OF LIFE; SEROGROUP; YOUNG ADULT;

EID: 84928923163     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123383     Document Type: Article

References (98)

1. Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012; 30 (24): 3710-6. doi: 10.1016/j.vaccine.2012.03.011 PMID: 22429756
2. Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Human vaccines & immunotherapeutics. 2013; 9(5): 1129-38.
3. Pollard AJ, Nadel S, Ninis N, Faust SN, Levin M. Emergency management of meningococcal disease: eight years on. Archives of disease in childhood. 2007; 92(4): 283-6. PMID: 17376933
4. Visintin C, Mugglestone MA, Fields EJ, Jacklin P, Murphy MS, Pollard AJ, et al. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. BMJ (Clinical research ed). 2010; 340: c3209. doi: 10.1136/bmj.c3209 PMID: 20584794
5. Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Vaccine. 2013; 31(23): 2638-46. doi: 10.1016/j.vaccine.2013.03.034 PMID: 23566946
6. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. The New England journal of medicine. 2010; 362(16): 1511-20. doi: 10.1056/NEJMra0906357 PMID: 20410516
7. EU-IBIS Network. Invasive Neisseria Meningitidis in Europe 2006. Health Protection Agency, London. 2006. Available: http://www.hpa-bioinformatics.org.uk/euibis/documents/2006-meningo.pdf.
8. Feavers I, Griffiths E, Baca-Estrada M, Knezevic I, Zhou T. WHO/Health Canada meeting on regulatory considerations for evaluation and licensing of new meningococcal Group B vaccines, Ottawa, Canada, 3-4 October 2011. Biologicals. 2012; 40(6): 507-16. doi: 10.1016/j.biologicals.2012.09.008 PMID: 23078946
9. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013; 381(9869): 825-35. PMID: 23324563
10. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009; 27 Suppl 2: B51-63. doi: 10.1016/j.vaccine.2009.04.063 PMID: 19477562
11. Kinlin LM, Jamieson F, Brown EM, Brown S, Rawte P, Dolman S, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine. 2009; 27(11): 1735-40. doi: 10.1016/j.vaccine.2009.01.026 PMID: 19186206
12. Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012; 379(9816): 617-24. doi: 10.1016/S0140-6736(11)61713-3 PMID: 22260988
13. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. The Lancet infectious diseases. 2013; 13(5):416-25. doi: 10.1016/S1473-3099(13)70006-9 PMID: 23414709
14. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. Journal of immunology. 1987; 138(12): 4402-7. PMID: 3108388
15. Nedelec J, Boucraut J, Garnier JM, Bernard D, Rougon G. Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis. Journal of neuroimmunology. 1990; 29(1-3): 49-56. PMID: 2211988
16. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012; 30 Suppl 2: B87-97. doi: 10.1016/j.vaccine.2012.01.033 PMID: 22607904
17. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. The Lancet infectious diseases. 2010; 10(2): 112-24. doi: 10.1016/S1473-3099(09)70324-X PMID: 20113980
18. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. The Pediatric infectious disease journal. 2010; 29(11): e71-9. doi: 10.1097/INF.0b013e3181f59f6d PMID: 20844462
19. Caugant DA, Maiden MC. Meningococcal carriage and disease - population biology and evolution. Vaccine. 2009; 27 Suppl 2: B64-70. doi: 10.1016/j.vaccine.2009.04.061 PMID: 19464092
20. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC infectious diseases. 2010; 10: 175. doi: 10.1186/1471-2334-10-175 PMID: 20565757
21. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000; 287(5459): 1816-20. PMID: 10710308
22. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(29): 10834-9. PMID: 16825336
23. Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010; 28(31): 5023-30. doi: 10.1016/j.vaccine.2010.05.014 PMID: 20493284
24. U.S. Food and Drug Administration. Vaccines, Blood & Biologics: Trumenba. U.S. Department of Health and Human Services. 2015. Available: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm421020.htm.
25. Novartis Vaccines and Diagnostics. Novartis receives positive CHMP opinion for Bexsero, a ground-breaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe. Novartis. 2012. Available: http://www.novartis.com/newsroom/media-releases/en/2012/1658747.shtml.
26. U.S. Food and Drug Administration. News & Events: FDA approves a second vaccine to prevent serogroup B meningococcal disease. U.S. Department of Health and Human Services. 2015. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm431370.htm.
27. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008/2009. ECDC. 2009. Available: http://www.ecdc.europa.eu/en/publications/Publications/1107-SUR-IBD-2008-09.pdf.
28. Andrus JK, Toscano CM, Lewis M, Oliveira L, Ropero AM, Dávila M, et al. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public health reports. 2007; 122(6): 811-6. PMID: 18051674
29. Burchett HE, Mounier-Jack S, Griffiths UK, Mills AJ. National decision-making on adopting new vaccines: a systematic review. Health policy and planning. 2012; 27 Suppl 2: ii62-76. doi: 10.1093/heapol/czr049 PMID: 21733989
30. Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine. 2011; 29(49): 9171-6. doi: 10.1016/j.vaccine.2011.08.005 PMID: 21839794
31. Piso B, Wild C. Decision support in vaccination policies. Vaccine. 2009; 27(43): 5923-8. doi: 10.1016/j.vaccine.2009.07.105 PMID: 19698809
32. World Health Organization. Vaccine Introduction Guidelines. Adding a vaccine to a national immunization programme: decision and implementation. WHO. 2005. Available: http://www.who.int/immunization/hpv/plan/vaccine-introduction-guidelines-who-2005.pdf.
33. Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach J. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC medicine. 2011; 9: 55. doi: 10.1186/1741-7015-9-55 PMID: 21569407
34. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC medicine. 2013; 11: 80. doi: 10.1186/1741-7015-11-80 PMID: 23531108
35. European Centre for Disease Prevention and Control. European Invasive Bacterial Diseases Surveillance Network (EU-IBD). ECDC. 2013. Available: http://www.ecdc.europa.eu/en/activities/surveillance/eu-ibd/Pages/index.aspx.
36. DG Health and Food Safety - Public Health - Communicable diseases. Legislation on Communicable diseases. European Commission. 2013. Available: http://ec.europa.eu/health/communicable-diseases/early-warning/comm-legislation-en.htm.
37. Ministero della Salute. La scheda di dimissione ospedaliera (SDO). 2014. Available: http://www.salute.gov.it/portale/temi/p2-6.jsp?lingua = italiano&id=1232&area = ricoveriOspedalieri&menu = vuoto.
38. Ministero della Salute. Il sistema DRG. 2013. Available: http://www.salute.gov.it/portale/temi/p2-5.jsp?lingua = italiano&area = ricoveriOspedalieri&menu = sistema.
39. Istituto Nazionale di Statistica. Demografia in Cifre. ISTAT. 2013. Available: http://demo.istat.it/.
40. di Pietro ML, Capri S, Kheirauoi F, deWaure C, Quaranta G, Poscia A, et al. Health technology assessment della vaccinazione contro meningococco B. Italian journal of public health. 2013; 2(13).
41. Ginsberg L. Difficult and recurrent meningitis. Journal of neurology, neurosurgery and psychiatry. 2004; 75 Suppl1: i16-21.
42. AIES. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEconomics - Italian Research Articles. 2009; 11(2): 83-93.
43. Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: Recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Information Journal. 2001; 35: 189-201.
44. Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014; 349: 5725.
45. Istituto Superiore di Sanità - Gruppo di Lavoro del CNESPS. Dati e evidenze disponibili per l'introduzione della vaccinazione anti-meningococco B nei nuovi nati e negli adolescenti. ISS. 2014. Available: http://www.epicentro.iss.it/temi/vaccinazioni/pdf/Istruttoria%20MENINGOCOCCO%20B.pdf.
46. Lucioni C, Alliata E, Mazzi S, Lizioli A. I costi della meningite pneumococcica in età pediatrica. PharmacoEconomics - Italian Research Articles. 2005; 7(3): 177-186.
47. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. The Lancet infectious diseases. 2010; 10(5): 317-28. doi: 10.1016/S1473-3099(10)70048-7 PMID: 20417414
48. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. The Pediatric infectious disease journal. 1993; 12(5): 389-94. PMID: 8327300
49. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clinical infectious diseases. 2001; 33(5): 737-9. PMID: 11477523
50. Regione Autonoma della Sardegna - ASL no 7 Carbonia. Delibera 737. 2014. Available: http://www.aslcarbonia.it/documenti/7-49-20140512170353.pdf.
51. Regione Lazio - ASL Roma F. Delibera 1195. 2014. Available: http://www.aslrmf.it/joomla/pdf/delibere/2014/1195-26.11.14.pdf.
52. Giorgi-Rossi P, Merito M, Borgia P. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy. Health policy. 2009; 89(2): 225-38. doi: 10.1016/j.healthpol.2008.05.016 PMID: 18639952
53. European Medicines Agency. Bexsero Summary of Product Characteristics. EMA. 2013. Available: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002333/WC500137881.pdf.
54. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012; 307(6): 573-82. doi: 10.1001/jama.2012.85 PMID: 22318278
55. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005; 23(17-18): 2191-6.
56. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. American journal of epidemiology. 2007; 166(7): 817-823. PMID: 17615088
57. Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clinical and vaccine immunology. 2010; 17(6): 919-29. doi: 10.1128/CVI.00027-10 PMID: 20375242
58. Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine. 2013; 32(1): 124-30. doi: 10.1016/j.vaccine.2013.03.063 PMID: 23588089
59. Joint Committee on Vaccination and Immunisation. JCVI interim position statement on the use of Bexsero meningococcal B vaccine in the UK. Department of Health. 2013. Available: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/224896/JCVI-interim-statement-on-meningococcal-B-vaccination-for-web.pdf.
60. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004; 364(9431): 365-7. PMID: 15276396
61. Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. The pediatric infectious disease journal. 2013; 32(10): 1116-21. doi: 10.1097/INF.0b013e31829cfff2 PMID: 23958808
62. Santolaya ME, O'Ryan M, Valenzuela MT, Prado V, Vergara RF, Muñoz A, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Human vaccines & immunotherapeutics. 2013; 9(11): 2304-10.
63. Bos JM, Rümke HC, Welte R, Postma MJ, Jager JC. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine. 2001; 20(1-2): 202-7.
64. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. NICE. 2013. Available: http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf.
65. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe. ECDC. 2011. Available: http://www.ecdc.europa.eu/en/publications/Publications/1107-SUR-IBD-2008-09.pdf.
66. Giorgi Rossi P, Mantovani J, Ferroni E, Forcina A, Stanghellini E, Curtale F, et al. Incidence of bacterial meningitis (2001-2005) in Lazio, Italy: the results of an integrated surveillance system. BMC infectious diseases. 2009; 9: 13. doi: 10.1186/1471-2334-9-13 PMID: 19196453
67. Le Haut Conseil de la santé publique. Vaccination contre les infections invasives à méningocoque B Place Bexsero. HCSP. 2013. Available: www.hcsp.fr/Explore.cgi/Telecharger?NomFichier = hcspr20131025-vaccmeningocoqueBBexsero.pdf.
68. Hong AT, Deeks S, Morris S, Strifler L, Crowcroft N, Jamieson F, et al. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. 35th Annual Meeting of the Society for Medical Decision Making. Baltimore. 2013. Available: https://smdm.confex.com/smdm/2013md/webprogram/Paper7606.html.
69. Committee on Immunisation Programmes and Registries. Criteria for the assessment of changes in the immunisation programme in Spain. 2013. Available: www.msssi.gob.es/ciudadanos/proteccionSalud/vacunaciones/docs/Criterios-ProgramaVacunas.pdf.
70. Joint Committee on Vaccination and Immunisation. JCVI interim position statement on the use of Bexsero meningococcal B vaccine in the UK. Department of Health. 2014. Available: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/294245/JCVI-Statement-on-MenB.pdf.
71. Andrews SM, Pollard AJ. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. The Lancet infectious diseases. 2014; 14(5): 426-34. doi: 10.1016/S1473-3099(13)70341-4 PMID: 24679664
72. Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013; 31(43): 4968-74. doi: 10.1016/j.vaccine.2013.08.006 PMID: 23954380
73. Dellicour S, Greenwood B. Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Tropical medicine & international health. 2007; 12(12): 1409-21.
74. Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon S, et al. Impact of a quadrivalent conjugate (MenACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. Poster abstract 31st annual meeting of the European Society of Paediatric Infectious Disease meeting 2013. 2013. Available: http://www.abstractserver.com/espid2013/planner/index.php?go = abstract&action = abstract-iplanner&print=0&absno=1472&1.
75. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Medical decision making. 2006; 26(1): 38-47. PMID: 16495199
76. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert review of vaccines. 2009; 8(7): 851-61. doi: 10.1586/erv.09.48 PMID: 19538112
77. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value in health. 2004; 7(4): 397-401. PMID: 15449631
78. Hillman AL, Kim MS. Economic decision making in healthcare. A standard approach to discounting health outcomes. PharmacoEconomics. 1995; 7(3): 198-205. PMID: 10155309
79. Tasset A, Nguyen VH, Wood S, Amazian K. Discounting: technical issues in economic evaluations of vaccination. Vaccine. 1999; 17 Suppl 3: S75-80. PMID: 10559540
80. Meyerhoff AS, Jacobs RJ. Do too many shots due lead to missed vaccination opportunities? Does it matter? Preventive medicine. 2005; 41(2): 540-4. PMID: 15917050
81. Lennon D. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine. 2007; 25(16): 3075-9. PMID: 17289223
82. Health Council (GezondheidsRaad; GR). The future of the national immunization program: Towards a program for all ages. The Health Council of the Netherlands. 2007. Available: http://www.gezondheidsraad.nl/sites/default/files/200702E-0.pdf.
83. Krabbe PF, Hinderink JB, van den Broek P. The effect of cochlear implant use in postlingually deaf adults. International journal of technology assessment in health care. 2000; 16: 864-73. PMID: 11028141
84. Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. Journal of clinical epidemiology. 2002; 55(8): 791-9. PMID: 12384194
85. McNicholas A, Galloway Y, Stehr-Green P, Reid S, Radke S, Sexton K, et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Human vaccines. 2007; 3(5):196-204. PMID: 17660718
86. Agenzia Nazionale per i Servizi Sanitari Regionali. Ricoveri ospedalieri. I sistemi tariffari regionali vigenti nell'anno 2009. AGENAS. 2010. Available: http://www.agenas.it/.
87. Gottfredsson M, Reynisson IK, Ingvarsson RF, Kristjansdottir H, Nardini MV, Sigurdsson JF, et al. Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clinical infectious diseases. 2011; 53(9): e117-24. doi: 10.1093/cid/cir500 PMID: 21946191
88. Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet neurology. 2012; 11(9): 774-783. doi: 10.1016/S1474-4422(12)70180-1 PMID: 22863608
89. Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clinical infectious diseases. 2008; 46(1): 1-13. doi: 10.1086/524041 PMID: 18171206
90. Thein HH, Gomes T, Krahn MD, Wodchis WP. Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario. Quality of life research. 2010; 19(1): 81-9. doi: 10.1007/s11136-009-9563-2 PMID: 20033300
91. Donev D, Zaletel-Kragelj L, Bjegovic V, Burazeri G. Measuring the burden of disease: Disability Adjusted Life Year (DALY). 2010. Available: http://www.mf.uni-lj.si/dokumenti/6b695fc9385e3e2ab8fb41ec7d34660d.pdf.
92. Caban-Martinez AJ, Lee DJ, Fleming LE, Tancredi DJ, Arheart KL, LeBlanc WG, et al. Arthritis, occupational class, and the aging US workforce. American journal of public health. 2011; 101(9): 1729-34. doi: 10.2105/AJPH.2011.300173 PMID: 21778483
93. Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, et al. Impact of psychiatric disorders on health-related quality of life: general population survey. The British journal of psychiatry. 2007; 190: 326-32. PMID: 17401039
94. Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. The British journal of ophthalmology. 2001; 85(3): 327-31. PMID: 11222340
95. Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ. Kramers PNG, et al. Disability weights for diseases: a modified protocol and results for a Western European region. European journal of public health. 1999; 10(1): 24-30.
96. Yfantopoulos J. Quality of life and QALYs in the measurement of health. Archives of Hellenic medicine. 2001; 18(2): 114-130.
97. Xu R, Insinga RP, Golden W, Hu XH. EuroQol (EQ-5D) health utility scores for patients with migraine. Quality of life research. 2011; 20(4): 601-8. doi: 10.1007/s11136-010-9783-5 PMID: 21063786
98. Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS medicine. 2012; 9(9): e1001307. doi: 10.1371/journal.pmed.1001307 PMID: 22984353